August 22, 2014Circulation
Central Sympathetic Inhibition to Reduce Postablation Atrial Fibrillation Recurrences in Hypertensive Patients
Why the study?
Does moxonidine reduce postablation atrial fibrillation recurrence in hypertensive patients with symptomatic paroxysmal atrial fibrillation?
Population
291 hypertensive patients with symptomatic paroxysmal atrial fibrillation scheduled to undergo pulmonary…
Comparison
Moxonidine added to standard antihypertensive… vs Placebo added to standard antihypertensive…
Design
RCT, randomly assigned, double-blinded
Follow-up
12 months
Authors
Discussion
Loading...
Member takes
Implication
Moxonidine reduces post-PVI AF recurrence in hypertensive paroxysmal AF; supports adjunctive use and further outcome trials.
Structured PICO
Does moxonidine reduce postablation atrial fibrillation recurrence in hypertensive patients with symptomatic paroxysmal atrial fibrillation?
P
Population
291 hypertensive patients with symptomatic paroxysmal atrial fibrillation (drug-refractory) scheduled to undergo pulmonary vein isolation
I
Intervention
Moxonidine (0.2-0.4 mg daily) added to standard antihypertensive treatment
C
Comparator
Placebo added to standard antihypertensive treatment
O
Outcome
Postablation atrial fibrillation recurrence
In hypertensive patients undergoing pulmonary vein isolation for paroxysmal atrial fibrillation, the addition of the centrally acting sympathoinhibitory agent moxonidine significantly reduces the risk of postablation AF recurrence.
Cite This Study
Γιαννόπουλος et al. (2014) studied this question.